news
Press release
 
April 9, 2015
University of Virginia Health System Installs Second CorPath System®, Supports UVA “Be Safe” Initiative for Patients and Staff

CorPath’s radiation protection capability a key part of “Be Safe”

Waltham, MA – April 9, 2015Corindus Vascular Robotics [OTCQB: CVRS], a leading developer of precision vascular robotics, today announced that the University of Virginia Health System (UVA) has installed a second CorPath System, the only FDA-cleared system for robotic-assisted PCI. The second system supports UVA’s continuing efforts behind its “Be Safe” initiative, which is designed to make the health system the safest place in healthcare for patients and employees alike. The initiative focuses on training UVA team members to identify issues that improve safety, workflow and outcomes by increasing protection of operators in the cath lab, where risks from harmful radiation exposure and traditional protection methods continue to be a major concern.

“Using robotic-assisted PCI, we are able to protect interventional cardiologists from the orthopedic strain and risks of radiation exposure while performing interventional procedures,” said Michael Ragosta, MD, Medical Director for Interventional Cardiology, UVA. “Beyond the safety advances afforded by the system, the enhanced precision, visualization and measurement may lead to improved patient care.”

During a CorPath robotic-assisted PCI procedure, the interventional cardiologist sits in the radiation shielded interventional cockpit, and advances guidewires and stents with millimeter-by-millimeter precision. Along with the addition of robotic precision to procedures, the PRECISE clinical trial1 demonstrated that while using the CorPath System physician radiation exposure during procedures was reduced by 95 percent.

For more information, visit www.corindus.com.

1PRECISE Trial was sponsored by Corindus, Inc.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window